

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C07D 417/12, A61K 31/445, A61M 5/142	A1	(11) International Publication Number: <b>WO 97/15572</b>
		(43) International Publication Date: 1 May 1997 (01.05.97)

(21) International Application Number: PCT/EP96/04608

(22) International Filing Date: 21 October 1996 (21.10.96)

(30) Priority Data:  
95202887.6 25 October 1995 (25.10.95) EP

(34) Countries for which the regional or international application was filed: DE et al.

(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): STOKBROECKX, Raymond, Antoine [BE/BE]; Rode Kruisstraat 17, B-2340 Beerse (BE).

(74) Agent: DE CORTE, Filip; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).


Published

With international search report.


(54) Title: LUBELUZOLE N-OXIDE

(57) Abstract

The present invention is concerned with lubeluzole N-oxide(s), compositions containing the N-oxide(s), methods of preparing these and their use as a medicine, in particular in the treatment of conditions involving cerebral hypoxia.



[cis, (S)]



[trans, (S)]

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## LUBELUZOLE N-OXIDE

---

5 The present invention is concerned with neuroprotectant N-oxide forms of lubeluzole, compositions containing such N-oxide(s), methods of preparing these and their use as a medicine, in particular in the treatment of conditions involving cerebral hypoxia.



10 In US-4,861,785 there are described benzoxazol- and benzothiazolamine derivatives having anti-hypoxic and anti-anoxic activity. In WO-92/14,731 some of these benzothiazolamine derivatives were disclosed having useful anti-stroke activity. Injectable formulations of (S)-4-[(2-benzothiazolyl) methylamino]- $\alpha$ -[(3,4-difluorophenoxy)methyl]-1-piperidine-ethanol (generically known as lubeluzole) are disclosed in European Patent application No. 94203422.4 filed 24 November 1994.

15 Conditions involving cerebral hypoxia comprise stroke, more in particular ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage, and head trauma. The treatment of conditions involving cerebral hypoxia currently consists mainly of neuroprotective and of haematologic therapeutic strategies. Optimal therapies remain to be determined. Such an optimized therapy for the treatment of hypoxia is the subject of the present invention. In particular, it concerns providing an N-oxide of lubeluzole, a pharmaceutically acceptable acid addition salt form, a solvate or a stereochemically isomeric form thereof, as a new medicine for the treatment of conditions involving cerebral hypoxia. The product is suitable for intravenous and intradermal  
20 administration by infusion which is the most appropriate route of administration for hypoxic patients, and also orally, which route is most suitable for maintenance therapy. Experiments with the cis N-oxide form of lubeluzole in an animal model test of acute stroke indicate that it has superior neuroprotectant activity over the compound lubeluzole.

30 The N-oxides of lubeluzole are meant to comprise those compounds wherein one or more of the nitrogen atoms are oxidized, in particular those wherein the piperidine nitrogen is oxidized.

35 More in particular, the present invention is concerned with lubeluzole N-oxide, the cis and trans forms of which are represented by the following formulae :

-2-



Pharmaceutically acceptable acid addition salts comprise the therapeutically active, non-toxic salt forms obtained by treating a base form with an acid such as, for example, an inorganic acid, e.g. hydrochloric, hydrobromic, sulfuric, nitric, phosphoric acid ; or an organic acid, e.g. acetic, propanoic, hydroxyacetic, lactic, pyruvic, malonic, succinic, maleic, fumaric, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic acid. Solvates of lubeluzole N-oxide are, for example hydrates, alcoholates.

The cis-oriented N-oxide of lubeluzole is particularly preferred, and the most preferred form thereof is the hemihydrate, i.e. (-)-[cis] lubeluzole N-oxide hemihydrate.

The N-oxide(s) of lubeluzole can be prepared following art-known procedures of preparing oxides of nitrogen-containing products. They are conveniently prepared by dissolving lubeluzole in a solvent and adding thereto a sufficient amount of a suitable oxidant. Examples of such oxidants are hydrogen peroxide, peroxic acids, e.g. *m*-chloroperbenzoic acid, metal oxides, e.g. NaWO<sub>4</sub> and the like. Suitable solvents are, for example, water and halogenated hydrocarbons, in particular dichloromethane.

Hereinafter, the amounts of each of the ingredients in liquid compositions are expressed as percentages by weight based on the total volume of the formulation, unless otherwise indicated. Amounts in solid preparations are expressed as percentages by weight based on the total weight of the formulation, unless otherwise indicated.

Pharmaceutical compositions of lubeluzole N-oxide suitable as medicaments according to the present invention comprise a pharmaceutically effective amount of active ingredient and one or more pharmaceutically acceptable excipients or carriers as known in the art. The pharmaceutical compositions are adapted for oral or parenteral

(including intramuscular, subcutaneous, intradermal and intravenous) administration. The formulations are most conveniently presented in discrete dosage units. Generally, the pharmaceutically acceptable carrier for formulating the neuroprotectant lubeluzole N-oxide as an infusion is an aqueous solution (a) comprising water ; an isotonicizing agent ; and acid, base or buffer substances sufficient to adjust the pH of the solution in the range of from 2.5 to 3.6.

In particular, the concentration of lubeluzole N-oxide in the present solutions (a) may range from 0.005% to 5%, preferably from 0.01% to 1%, more preferably from 0.02% to 0.2% and in particular is about 0.05%.

Further, the present solutions (a) conveniently comprise from 1 to 10% isotonicizing agent. The use of glucose as isotonicizing agent has the advantage that very clear solutions are obtained. Preferably, glucose is used in a concentration from 2 to 10%, most preferably of about 5%.

The solutions (a) further comprise acid and base substances to maintain the pH of the solution in the range from 2.5 to 3.6, preferably in the range from 3.0 to 3.4, most preferably at about 3.2. Preferably, the pH of the solutions (a) is adjusted by appropriate amounts of hydrochloric acid and sodium hydroxide. The pH may also be adjusted by buffer systems comprising mixtures of appropriate amounts of an acid such as phosphoric, tartaric or citric acid, and a base, in particular sodium hydroxide.

In order to increase the solubility of lubeluzole N-oxide in the present formulations, a solubilizer may be used. Conveniently, a cyclodextrin (CD) or a derivative thereof may be used. Appropriate cyclodextrin derivatives are  $\alpha$ -,  $\beta$ -,  $\gamma$ -cyclodextrins or ethers and mixed ethers thereof wherein one or more of the hydroxy groups of the anhydroglucose units of the cyclodextrin are substituted with C<sub>1</sub>-alkyl, particularly methyl, ethyl or isopropyl, e.g. randomly methylated  $\beta$ -cyclodextrin; hydroxy-C<sub>1</sub>-alkyl, particularly hydroxyethyl, hydroxypropyl or hydroxy-butyl; carboxy-C<sub>1</sub>-alkyl, particularly carboxymethyl or carboxyethyl; C<sub>1</sub>-alkyl-carbonyl, particularly acetyl; C<sub>1</sub>-alkyloxycarbonyl-C<sub>1</sub>-alkyl or carboxyC<sub>1</sub>-alkyloxy-C<sub>1</sub>-alkyl, particularly carboxymethoxypropyl or carboxyethoxy-propyl; C<sub>1</sub>-alkyl-carbonyloxyC<sub>1</sub>-alkyl, particularly 2-acetyloxypropyl. Especially noteworthy as solubilizers are  $\beta$ -CD, 2,6-dimethyl- $\beta$ -CD, randomly methylated  $\beta$ -cyclo-dextrin, 2-hydroxyethyl- $\beta$ -CD, 2-hydroxyethyl- $\gamma$ -CD, 2-hydroxypropyl- $\gamma$ -CD and (2-carboxymethoxy)propyl- $\beta$ -CD, and in particular 2-hydroxypropyl- $\beta$ -CD.

The term mixed ether denotes cyclodextrin derivatives wherein at least two cyclodextrin hydroxy groups are etherified with different groups such as, for example, hydroxypropyl and hydroxyethyl.

5 The average molar substitution (M.S.) is used as a measure of the average number of moles of alkoxy units per mole of anhydroglucose. The M.S. value can be determined by various analytical techniques such as nuclear magnetic resonance (NMR), mass spectrometry (MS) and infrared spectroscopy (IR). Depending on the technique used, slightly different values may be obtained for one given cyclodextrin derivative. In the cyclodextrin hydroxyalkyl derivatives for use in the compositions according to the present invention the M.S. as determined by mass spectrometry is in the range of 0.125  
10 to 10, in particular of 0.3 to 3, or from 0.3 to 1.5. Preferably the M.S. ranges from about 0.3 to about 0.8, in particular from about 0.35 to about 0.5 and most particularly is about 0.4. M.S. values determined by NMR or IR preferably range from 0.3 to 1, in particular from 0.55 to 0.75.

15 The average substitution degree (D.S.) refers to the average number of substituted hydroxyls per anhydroglucose unit. The D.S. value can be determined by various analytical techniques such as nuclear magnetic resonance (NMR), mass spectrometry (MS) and infrared spectroscopy (IR). Depending on the technique used, slightly different values may be obtained for one given cyclodextrin derivative. In the cyclodextrin derivatives for use in the compositions according to the present invention  
20 the D.S. as determined by MS is in the range of 0.125 to 3, in particular of 0.2 to 2 or from 0.2 to 1.5. Preferably the D.S. ranges from about 0.2 to about 0.7, in particular from about 0.35 to about 0.5 and most particularly is about 0.4. D.S. values determined by NMR or IR preferably range from 0.3 to 1, in particular from 0.55 to  
25 0.75.

More particular  $\beta$ - and  $\gamma$ -cyclodextrin hydroxyalkyl derivatives for use in the compositions according to the present invention are partially substituted cyclodextrin derivatives wherein the average degree of alkylation at hydroxyl groups of different positions of the anhydroglucose units is about 0% to 20% for the 3 position, 2% to 70%  
30 for the 2 position and about 5% to 90% for the 6 position. Preferably the amount of unsubstituted  $\beta$ - or  $\gamma$ -cyclodextrin is less than 5% of the total cyclodextrin content and in particular is less than 1.5%. Another particularly interesting cyclodextrin derivative is randomly methylated  $\beta$ -cyclodextrin.

Most preferred cyclodextrin derivatives for use in the present invention are those  
35 partially substituted  $\beta$ -cyclodextrin ethers or mixed ethers having hydroxypropyl, hydroxyethyl and in particular 2-hydroxypropyl and/or 2-(1-hydroxypropyl) substituents.

The most preferred cyclodextrin derivative for use in the compositions of the present invention is hydroxypropyl- $\beta$ -cyclodextrin having a M.S. in the range of from 0.35 to 0.50 and containing less than 1.5% unsubstituted  $\beta$ -cyclodextrin. M.S. values determined by NMR or IR preferably range from 0.55 to 0.75.

5

In order to minimize the risk of adverse reactions, an intravenous (or intradermal) formulation preferably contains as few ingredients as possible. Therefore, a formulation without a solubilizer such as a cyclodextrin is preferred. Further, the neuroprotectant solution (a) preferably does not contain a preservative. Oral liquid formulations on the other hand can comprise both a solubilizer such as a cyclodextrin and one or more preservatives.

In particular, the present invention relates to neuroprotectant solutions (a) comprising:

- (i) 0.005 to 5% lubeluzole N-oxide or a pharmaceutically acceptable addition salt or a solvate thereof;
- (ii) 1 to 10% isotonicizing agent;
- (iii) acid and/or base substances to adjust the pH in the range from 2.5 to 3.6 ; and
- (iv) water q.s. ad 100%.

Preferably, the invention relates to neuroprotectant solutions (a) comprising:

- (i) 0.01 to 1% lubeluzole N-oxide or a pharmaceutically acceptable addition salt or a solvate thereof;
- (ii) 2 to 10% glucose;
- (iii) hydrochloric acid and sodium hydroxide to adjust the pH in the range from 3.0 to 3.4 ; and
- (iv) water q.s. ad 100%.

Most preferably, the invention relates to neuroprotectant solutions (a) containing approximately :

- (i) 0.05% lubeluzole N-oxide or a pharmaceutically acceptable addition salt or a solvate thereof;
- (ii) 5% glucose;
- (iii) hydrochloric acid and sodium hydroxide to adjust the pH to about 3.2; and
- (iv) water q.s. ad 100%.

35

The solutions (a) are sterilized using art-known techniques.

The neuroprotectant solution (a) of the present product is conveniently used in the treatment of patients suffering from acute hypoxia. In general it is contemplated that

an effective treatment for acute hypoxia involves administering to the patient by infusion an amount of lubeluzole N-oxide in the range of 10 to 30 ml of solution (a) or from 5 to 15 mg of the active ingredient during the first hour of therapy. During the following 24 hours about 4/3 or 133% of that amount may be administered. That is, one starts with a relatively high initial flow which is then lowered considerably. The maintenance dose may be administered for several consecutive days.

Preferably about 15 ml of solution or about 7.5 mg of the active ingredient is administered by infusion during the first hour of therapy, followed by about 20 ml of solution or about 10 mg of active ingredient during the next 24 hours. It is evident that said effective amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compound of the instant invention. The effective amount ranges mentioned hereinabove are therefore guidelines only and are not intended to limit the scope or use of the invention to any extent.

The lubeluzole N-oxide solutions may conveniently be co-administered with a physiological salt solution following to art-known infusion procedures. They may also be accompanied by administration of other anti-hypoxic drugs such as NMDA receptor antagonists, e.g. aptiganel, eliprodil, selfotel, tirilazad or remacemide; antithrombotics, e.g. tPA, streptokinase, staphylokinase, heparin or similar agents.

Since the product is meant to be administered urgently to patients suffering from hypoxia, for example in the ambulance, emergency room or intense care unit, an infusion device or pack for the treatment of hypoxia comprising the product together with a disposable, independent drive unit is considered to be a most useful presentation of the product according to the present invention. As independent drive units for powering syringes, in particular prefilled syringes, there may be named both gas-operated and vacuum-operated drive. An interesting gas-operated intradermal drug delivery device permitting delivery of a drug at a slow rate which can be precisely controlled is described in WO-95/13838, corresponding to US-5,527,288. The device comprises a housing with one or more drug reservoirs and a single hollow needle projecting outwards for a sufficient distance so as to penetrate through the stratum corneum and epidermis into the dermis when the housing is pressed against the skin. The device can be of modular design consisting of disposable cartridge units comprising the depletable components (active ingredient, power source) and a reusable drive unit comprising amongst others the housing and the electronic controls.



The present invention evidently also concerns the use of a product as described hereinbefore for the preparation of a medicament for acute hypoxia treatment. Similarly, the present invention relates to a method of treating patients suffering from hypoxia, comprising administering to said patients a pharmaceutically effective amount of an N-oxide product as described hereinbefore.

#### Experimental part

##### Example 1 : Preparation of (-)-[cis] lubeluzole N-oxide hemihydrate.

To a stirred solution of lubeluzole (11.6 g ; 27 mmol) in dichloromethane (700 ml), cooled to -10°C, was added m-chloroperbenzoic acid (6.7 g ; 31 mmol). The reaction mixture was stirred for 24 hours, and then washed with an aqueous ammonia solution (2% ; 3 times) and water (3 times). The organic phase was dried on MgSO<sub>4</sub>, filtered and evaporated, yielding 9.6 of raw material. The product (-)-[cis] lubeluzole N-oxide hemihydrate was purified by recrystallization from methylisopropylketone (mp. 182.8°C) (yield : 4.7 g ; 38.7%)  $[\alpha]_D^{20} = -8.73^\circ$  (1% in methanol) (comp. 1).

##### Example 2 : Pharmacological example

The useful anti-hypoxic properties of the product of the present invention can be demonstrated in the following test procedure.

##### Post-Treatment in a Rat Photochemical Stroke Model.

Male Wistar rats, weighing 260-280 g, were anesthetized with halothane in a N<sub>2</sub>O/O<sub>2</sub> mixture. The animals were placed in a stereotactic apparatus, the scalp was incised for exposure of the skull surface, and a catheter was inserted into a lateral tail vein. Rose Bengal (30mg/kg; 15 mg/ml in 0.9% NaCl) was infused intravenously for 2 minutes in animals with normal hemodynamics and blood gases. Thereafter, the skull was focally illuminated with cold white light for 5 minutes by means of a fiber-optic bundle inside a 1-mm diameter objective. The light was aimed at the hindlimb area of the right parietal sensorimotor neocortex. Five minutes after infarct induction (i.e. 5 min after light offset), the rats are injected with either lubeluzole or lubeluzole N-oxide (comp.1). Neurologic tests, involving limb placing reactions, were conducted on the first two days after infarction at 24-hour intervals after its induction. Tactile forward and sideways placing were tested by lightly contacting the table edge with the dorsal or lateral aspect of a paw (2 tests). Proprioceptive forward and sideways placing involved pushing the paw against the table edge in order to stimulate limb muscles and joints (2 tests). Rats were also put along the edge of an elevated platform in order to assess

proprioceptive adduction : a paw was gently pulled down and away from the platform edge, and, upon sudden release, it was checked for retrieval and placing (1 test).

For each of the 5 tests, placing scores are : 0, no placing; 1, incomplete and/or delayed placing; or 2, immediate, complete placing. For each limb, the summed tactile/proprioceptive placing score, including the platform test, is maximally 10.

- 5 Results are reported from the deficient hindlimb contralateral to the neocortical infarct. Six rats are used for each dose.

compound	placing score (median)	minimum	maximum
lubeluzole	7.5	6	10
lubeluzole N-oxide	9.5	8	10



- 10 From these results one can conclude that the test animals receiving the lubeluzole N-oxide recover better from the induced stroke than those receiving lubeluzole itself.

Claims

1. An N-oxide form of lubeluzole, a pharmaceutically acceptable acid addition salt form, a solvate or a stereochemically isomeric form thereof.

2. An N-oxide according to claim 1 wherein the piperidine nitrogen is oxidized.

3. An N-oxide according to claim 2 wherein the cis and trans forms are represented by the formulae :



4. An N-oxide according to claim 1 wherein the compound is (-)-[cis] lubeluzole N-oxide hemihydrate.

5. A process of preparing an N-oxide of lubeluzole comprising the steps of dissolving lubeluzole in a solvent and adding thereto a sufficient amount of a suitable oxidant.

6. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound as claimed in any one of claims 1 to 4 and a pharmaceutically acceptable carrier.

7. A composition according to claim 6 adapted for oral or parenteral administration:

8. A composition according to claim 7 wherein the N-oxide is formulated in an aqueous solution comprising water ; an isotonicizing agent ; and acid, base or buffer substances sufficient to adjust the pH of the solution in the range of from 2.5 to 3.6.

9. A composition according to claim 8 wherein the neuroprotectant solution (a) comprises :
- (i) 0.005 to 5% lubeluzole N-oxide or a pharmaceutically acceptable addition salt or a solvate thereof;
  - 5 (ii) 1 to 10% isotonicizing agent;
  - (iii) acid and/or base substances to adjust the pH in the range from 2.5 to 3.6 ; and
  - (iv) water q.s. ad 100%.
10. A composition according to claim 8 wherein the neuroprotectant solution (a) comprises :
- 10 (i) 0.01 to 1% lubeluzole N-oxide or a pharmaceutically acceptable addition salt or a solvate thereof;
  - (ii) 2 to 10% glucose;
  - 15 (iii) hydrochloric acid and sodium hydroxide to adjust the pH in the range from 3.0 to 3.4 ; and
  - (iv) water q.s. ad 100%.
11. A composition according to claim 8 wherein the neuroprotectant solution (a) comprises :
- 20 (i) 0.05 % (w/v) lubeluzole N-oxide or a pharmaceutically acceptable acid addition salt or a solvate thereof ;
  - (ii) 5 % (w/v) glucose ;
  - (iii) hydrochloric acid and sodium hydroxide to adjust the pH to about 3.2 ; and
  - 25 (iv) water q.s. ad 100 %.
12. A composition according to claim 8 wherein the neuroprotectant solution (a) is present in an amount of from 10 to 30 ml, and comprises about 5 to 15 mg lubeluzole N-oxide.
13. A composition according to claim 8 wherein the neuroprotectant solution (a) is present in an amount of about 15 ml, and comprises about 7.5 mg lubeluzole N-oxide.
14. A composition according to claim 8 wherein the neuroprotectant solution (a) is present in an amount of about 20 ml, and comprises about 10 mg lubeluzole N-oxide.
- 35

15. An infusion device or pack for the treatment of stroke comprising an N-oxide product according to any one of claims 1 to 4, with a disposable, independent drive unit.
- 5 16. An infusion pack according to claim 15 wherein the independent drive unit is gas-operated or vacuum-operated.
17. A product as claimed in any one of claims 1 to 4 for use as a medicine.
- 10 18. A product as claimed in claim 17 for use in the treatment of conditions involving cerebral hypoxia.
19. A product as claimed in claim 17 for use in the treatment of stroke and head trauma.
- 15 20. A product as claimed in claim 17 for use in the treatment of ischaemic stroke, intracerebral haemorrhage and subarachnoidal haemorrhage..

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/EP 96/04608

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D417/12 A61K31/445 A61M5/142

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Maximum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than maximum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 501 552 A (JANSSEN PHARMACEUTICA NV) 2 September 1992 cited in the application see claims	1-7
Y	GB 2 078 729 A (BRISTOL MYERS CO) 13 January 1982 see the whole document	1-7
A	EP 0 184 257 A (JANSSEN PHARMACEUTICA NV) 11 June 1986	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

Date of the actual completion of the international search

15 January 1997

Date of making of the international search report

24.01.97

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-2046

Authorized officer

Henry, J

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/EP 96/04608

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0501552	02-09-92	AT-T- 131478	15-12-95
		AU-B- 649788	02-06-94
		AU-A- 1208592	15-09-92
		BG-A- 98068	30-06-94
		CN-A- 1064865	30-09-92
		CN-A- 1113437	20-12-95
		CN-A- 1117048	21-02-96
		DE-D- 69206787	25-01-96
		DE-T- 69206787	05-06-96
		WO-A- 9214731	03-09-92
		EP-A- 0573473	15-12-93
		ES-T- 2083737	16-04-96
		HK-A- 172296	20-09-96
		HU-A- 67695	28-04-95
		HU-A- 9500319	28-09-95
		IE-B- 69567	02-10-96
		IL-A- 100952	31-12-95
		IL-A- 113837	14-05-96
		JP-T- 6505012	09-06-94
		NZ-A- 241592	26-07-94
		NZ-A- 248437	26-07-94
		PL-B- 168791	30-04-96
		US-A- 5434168	18-07-95
		ZA-A- 9201341	24-08-93
GB-A-2078729	13-01-82	US-A- 4306069	15-12-81
		AT-B- 376422	26-11-84
		AU-B- 525564	11-11-82
		AU-A- 7080081	24-12-81
		BE-A- 889309	21-12-81
		CA-A- 1149388	05-07-83
		CH-A- 647761	15-02-85
		CY-A- 1363	07-08-87
		DE-A- 3123942	22-07-82
		FR-A- 2485007	24-12-81
		HK-A- 49687	03-07-87
		JP-C- 1361184	30-01-87
		JP-A- 57056459	05-04-82
		JP-B- 61024390	10-06-86
		KE-A- 3702	27-03-87

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/EP 96/04608

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A-2078729		LU-A- 83440	14-04-82
		NL-A- 8102899	18-01-82
		SE-B- 435058	03-09-84
		SE-A- 8103822	20-12-81
-----			
EP-A-0184257	11-06-86	AU-B- 582601	06-04-89
		AU-A- 5057485	17-07-86
		BG-B- 60431	31-03-95
		CA-A- 1260474	26-09-89
		CY-A- 1690	14-01-94
		HK-A- 49593	27-05-93
		IE-B- 58807	17-11-93
		JP-B- 7059578	28-06-95
		JP-A- 61137884	25-06-86
		SU-A- 1428203	30-09-88
		US-A- 5010198	23-04-91
		US-A- 4861785	29-08-89
-----			